Hero-banner

Corporate Profile

Hero-banner

Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program efruxifermin (EFX) to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Corporate Presentation
Corporate Presentation
Download

Share Price

Akero Therapeutics

Jun 29, 2022 11:28 AM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases from Akero

View All
Jun 27, 2022

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Jun 16, 2022

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million

Recent Events

View All
Jun 9, 2022 at 4:00 PM EDT

Jefferies Healthcare Conference

May 24, 2022 at 7:00 AM EDT

H.C. Wainwright Annual Global Life Sciences Conference

May 11, 2022 at 11:40 AM EDT

BofA Securities 2022 Healthcare Conference

Investor Contact

Christina Tartaglia
T: (212) 362-1200
IR@akerotx.com

Media Contact

T: (650) 487-6488
media@akerotx.com


Helpful Tools